With over a decade of cannabis reform advocacy with the National Organization for the Reform of Marijuana Laws (NORML), Bailey was Washington NORML’s Legislative Associate during the 2017-18 legislative sessions and the only lobbyist focused solely on recreational cannabis policy. He’s currently the consumer representative on the Washington State Liquor and Cannabis Board’s Cannabis Advisory Council and consults for regulators, licensees, and individuals. Bailey has a Bachelor of Arts in Interdisciplinary Studies from the University of Missouri-Columbia, and lives in Lacey, Washington with his wife.
Agency leadership discussed messaging for Cannabis 2.0, vapor products, hemp/CBD, and traceability while learning the latest numbers from the licensing division.
A NEW “PROHIBITION” on “flavored vapor products” was adopted by the State Board of Health in compliance with Governor Jay Inslee’s mandate creating unknowable economic and public health impacts.
The Board heard the latest information on the vaping-related public health scare and Washington state’s response in preparation for emergency rulemaking.
The Board approved proposed rules for vapor products and heard testimony calling for increased opportunities for African Americans in the 502 market.
The Board prepared to hasten new vapor product rules along towards implementation and learned rulemaking would be restarted to consider canopy adjustments for Tier 1 producers.
The agency gathered feedback on the expansive rewrite of rules covering administrative violation notices (AVNs) required by SB 5318, the Enforcement reorganization bill.
The Director briefed on the agency’s request legislation and the vaping-related health scare, which includes a new lawsuit in Pierce County filed against six cannabis product manufacturers.
The latest on all open rulemaking projects including a signal that WSLCB intends to modify vapor product regulation in response to a widely publicized health scare.
The WSLCB’s Cannabis 2.0 project is garnering the attention of leadership at other state agencies ahead of the 2020 legislative session.
A sparsely attended hearing provided an opportunity to learn more about the department’s Medical Marijuana Program, the patient registry, and upcoming rulemaking.